Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Payables (2024 - 2025)

Caris Life Sciences has reported Payables over the past 2 years, most recently at $39.2 million for Q4 2025.

  • Quarterly results put Payables at $39.2 million for Q4 2025, up 41.07% from a year ago — trailing twelve months through Dec 2025 was $39.2 million (up 41.07% YoY), and the annual figure for FY2025 was $39.2 million, up 41.07%.
  • Payables for Q4 2025 was $39.2 million at Caris Life Sciences, up from $29.0 million in the prior quarter.
  • Over the last five years, Payables for CAI hit a ceiling of $39.2 million in Q4 2025 and a floor of $27.8 million in Q4 2024.